Respiratory Syncytial Virus (RSV): Maternal and Infant Protection Program

  • RSV Maternal Vaccination Program: A single dose of maternal RSV vaccine Abrysvo® provided to people from 28 weeks of pregnancy to pass immunity to their infant, funded under the National Immunisation Program (NIP), commenced on 3 February 2025.
  • The 2025 seasonal RSV Infant Immunisation Program ended 30 September.

RSV Maternal Protection Program (Abrysvo)

RSV vaccines and RSV monoclonal antibody by age group or cohort

RSV vaccines and RSV monoclonal antibody by age group or cohort
Age group or cohort Abrysvo® 0.5ml (Pfizer) Arexvy® 0.5ml (GSK) BeyfortusTM (nirsevimab) 0.5/1.0ml (Sanofi)
Women from 28 weeks of pregnancy NIP funded Do Not Use Do Not Use
Infants and children ≤24 months Do Not Use Do Not Use SA program ended on 30 September 2025
People 50-59 years with medical risk factors Do Not Use Available privately based on clinical decision Do Not Use
All people ≥60 years including Aboriginal and Torres Strait Islander people Available privately based on clinical decision Available privately based on clinical decision Do Not Use

RSV Infant Protection Program (Beyfortus)

Clinical guidance

Dashboard

Resources for patients - Department of Health, Disability and Ageing

Resources for patients - SA Health